ReviewMedical oncology (Northwood, London, England)2025
Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxaliplatin is a platinum-based chemotherapeutic agent that is commonly used in the treatment of colorectal cancer and other types of cancers. Despite its widespread use, the efficacy of oxaliplatin is frequently undermined by the development of resistance. Recent advances in RNA biology have shown the important roles of circular RNAs (circRNAs) in modulating cancer progression and response to chemotherapeutic agents. These transcripts can influence sensitivity to oxaliplatin by regulating key pathways such as DNA damage repair, apoptosis, and epithelial-mesenchymal transition. This article explores the mechanistic roles of circRNAs in oxaliplatin resistance, their potential as predictive biomarkers, and future therapeutic strategies to overcome treatment limitations.
Indexed as
Identifiers
41364390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.